Another therapeutic target for the treatment of AD is the M1 muscarinic acetylcholine receptor (mAChR) and M1 PAMs and a partial agonist have emerged as promising strategy for improving cognitive function in AD (Scarpa, Hesse and Bradley, 2020; Abd-Elrahman and Ferguson, 2022; Nathan et al., 2022). This evidence concerns the gene CHRM1 and Alzheimer disease.